Study guide

13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy

Key Takeaways Explain This Topic AI

Compared with nonpregnant women not using hormones (about 1–5 VTE events per 10,000 woman-years), combined oral contraceptive users have about 3–9, pregnant women about 5–20, and postpartum women about 40–65 (ACOG).

Pregnancy-associated DVT is usually left-sided and often iliofemoral; compression ultrasound is first-line, and suspected PE is evaluated with leg ultrasound, chest radiograph, then V/Q scan or CT pulmonary angiography.

Direct oral anticoagulants are first-line for most nonpregnant patients, but pregnancy requires therapeutic low-molecular-weight heparin because warfarin and DOACs are avoided.

Anticoagulation for pregnancy-associated VTE continues through pregnancy and at least 6 weeks postpartum, for a minimum total of 3 months; LMWH and warfarin are compatible with breastfeeding.

After VTE, estrogen-containing contraception is avoided (US MEC Category 3–4), while progestin-only methods and the copper IUD remain options.

Last updated: October 2026

Why VTE Matters in Women's Health

Pulmonary embolism is a leading cause of pregnancy-related death, and estrogen exposure from contraception, pregnancy, and hormone therapy makes VTE a recurring exam theme. Clots form through Virchow's triad : venous stasis, endothelial injury, and hypercoagulability. Pregnancy adds all three, through compression of pelvic veins, delivery trauma, and increases in clotting factors with lower protein S.

Absolute VTE Risk Comparison (ACOG)

  • Group Approximate VTE Events per 10,000 Woman-Years
  • Nonpregnant, not using hormonal contraception 1–5
  • Combined oral contraceptive users 3–9
  • Pregnant 5–20
  • Postpartum (first 12 weeks) 40–65

This comparison is useful for counseling: a combined pill raises risk, but far less than the pregnancy it prevents. Risk is highest in the first 3–6 weeks postpartum , especially after cesarean birth.

Risk Factors

Inherited thrombophilias: Factor V Leiden (most common), prothrombin G20210A, and deficiencies of protein C, protein S, and antithrombin (antithrombin deficiency carries the highest risk).

Acquired: Antiphospholipid syndrome, prior VTE (the strongest single predictor), obesity, smoking, immobility, surgery, cancer, long-distance travel, oral estrogen, older age, preeclampsia, cesarean birth, postpartum hemorrhage, infection, and multiple gestation.

  • Diagnosis
  • Nonpregnant Patients

Estimate pretest probability (Wells score).

With low probability, a negative D-dimer excludes VTE.

With high probability or a positive D-dimer: compression ultrasound for suspected DVT and CT pulmonary angiography (CTPA) for suspected PE (a V/Q scan when contrast is contraindicated).

Pregnant Patients

D-dimer rises normally in pregnancy, so it is less useful (pregnancy-adapted algorithms such as YEARS can still help).

About 85% of pregnancy-related DVTs are left-sided , and many involve the iliofemoral veins. Start with compression ultrasound ; if it is negative but suspicion for iliac thrombosis is high, use MR venography or serial ultrasound.

Suspected PE: If leg symptoms are present, compression ultrasound first (a positive study justifies treatment). Otherwise, obtain a chest radiograph: if it is normal, a V/Q scan is preferred; if abnormal, CTPA . Radiation from either test is far below doses associated with fetal harm, and diagnosis should never be withheld.

Presentation

DVT: Unilateral calf or thigh pain, swelling (a calf circumference difference of 2 cm or more), warmth, and erythema.

PE: Sudden dyspnea, pleuritic chest pain, tachycardia, hypoxemia, hemoptysis, and syncope. In pregnancy, these overlap with normal symptoms, so maintain a low threshold for testing.

Treatment

Setting Preferred Anticoagulant Notes

Nonpregnant DOACs (apixaban, rivaroxaban) for most At least 3 months; longer for unprovoked or persistent risk. Stop estrogen. DOACs, especially rivaroxaban, can worsen heavy menstrual bleeding (an LNG-IUS helps)

Pregnancy Therapeutic LMWH (for example, enoxaparin 1 mg/kg every 12 hours) Continue through pregnancy and at least 6 weeks postpartum , minimum total of 3 months. Warfarin (embryopathy, fetal bleeding) and DOACs (cross the placenta) are avoided

Breastfeeding LMWH, unfractionated heparin, or warfarin DOACs are not recommended during lactation

Delivery planning: Many patients switch to unfractionated heparin near term or have a planned induction so neuraxial anesthesia is possible; neuraxial placement generally waits 24 hours after a therapeutic LMWH dose and 12 hours after a prophylactic dose. Massive PE with hemodynamic instability may require thrombolysis or embolectomy even in pregnancy.

Thromboprophylaxis in Pregnancy (ACOG Practice Bulletin 196)

Prior VTE with a high-risk thrombophilia, or multiple prior VTEs: Prophylactic or intermediate-dose LMWH antepartum and for 6 weeks postpartum (therapeutic dosing if on long-term anticoagulation).

Single prior VTE that was unprovoked or related to pregnancy or estrogen: Antepartum and postpartum prophylaxis.

Single prior VTE with a transient non-hormonal cause (for example, trauma): Surveillance during pregnancy and postpartum prophylaxis.

All cesarean births: Pneumatic compression devices before surgery and until ambulation for patients not already on anticoagulation; LMWH is added for higher-risk patients.

Encourage early ambulation and hydration after every birth.

Contraception and Hormone Therapy After VTE

Combined hormonal contraception: US MEC Category 4 for acute VTE or a history with higher recurrence risk, and Category 3 for a history with lower recurrence risk.

Progestin-only methods (implant, LNG-IUD, POPs) are Category 2, and the copper IUD is Category 1. On long-term anticoagulation, heavy bleeding is a concern, which favors the LNG-IUD.

Menopausal hormone therapy: Systemic estrogen is generally avoided after VTE; if it is strongly needed, a transdermal route is preferred after specialist input. Nonhormonal options (SSRIs, SNRIs, fezolinetant, elinzanetant) are first-line for hot flashes.

Superficial thrombophlebitis: Warm compresses and NSAIDs (outside late pregnancy); obtain ultrasound if the clot is near the saphenofemoral junction or extends, because it can coexist with DVT.

Counseling Pearls

Thrombophilia testing is not routine before prescribing combined contraception. Take a careful personal and family history instead; test when a first-degree relative had VTE at a young age or a known familial thrombophilia exists.

Timing of thrombophilia tests: Protein C, protein S, and antithrombin levels are unreliable during an acute clot, during anticoagulation, and in pregnancy (protein S falls normally), so defer them or use genetic tests (factor V Leiden, prothrombin G20210A).

Progestin type matters: Combined pills containing desogestrel, gestodene, cyproterone, or drospirenone carry roughly 1.5–2 times the VTE risk of levonorgestrel-containing pills, although absolute risk stays small.

Air travel and surgery: Advise hydration, walking, and calf exercises on long flights, and assess VTE risk before major surgery in patients taking estrogen.